Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ALLK save search
Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis
Published: 2022-09-09 (Crawled : 22:00) - biospace.com/
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -8.41%
H: 18.12%
C: 15.41%
topline study
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
Published: 2022-09-19 (Crawled : 13:00) - biospace.com/
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 16.59%
H: 14.79%
C: 9.36%
offering
Allakos Announces a Restructuring to Focus on Development of AK006
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -59.2%
H: 10.66%
C: -2.46%
ak006
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -59.2%
H: 10.66%
C: -2.46%
urticaria dermatitis trials
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 1.49%
H: 10.29%
C: 2.21%
ak006 publication cell
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 2.21%
H: 10.07%
C: 5.04%
ak006 cell preclinical
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
Published: 2022-11-29 (Crawled : 12:20) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 0.54%
H: 9.19%
C: 7.3%
ak006 communications publication
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-01 (Crawled : 23:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -2.02%
H: 7.5%
C: 4.5%
financial results report results
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
Published: 2023-05-09 (Crawled : 20:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 0.46%
H: 5.54%
C: -0.92%
business update financial results
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
Published: 2023-06-12 (Crawled : 11:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 0.0%
H: 5.21%
C: 2.71%
ak006 cell preclinical
Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Published: 2021-03-01 (Crawled : 13:03) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 0.07%
H: 4.76%
C: -2.46%
financial results results
Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)
Published: 2021-06-07 (Crawled : 18:00) - biospace.com/
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -0.12%
H: 4.21%
C: 2.01%
phase 2 clinical trials phase 2/3 phase 3 trial enroll
Allakos Appoints Natalie Holles to its Board of Directors
Published: 2020-12-22 (Crawled : 22:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 0.67%
H: 3.59%
C: 3.08%
Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases
Published: 2021-12-22 (Crawled : 01:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -87.46%
H: 2.55%
C: -19.19%
phase 2 phase 2/3 gastrointestinal disease test topline phase 3
Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 3.43%
H: 2.45%
C: 0.79%
ema
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting
Published: 2021-10-24 (Crawled : 20:20) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 3.43%
H: 2.45%
C: 0.79%
presentation disease
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -1.15%
H: 2.33%
C: 1.55%
business year update financial results
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
Published: 2022-11-10 (Crawled : 16:00) - biospace.com/
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 3.6%
H: 2.17%
C: 2.17%
ak007 preclinical immunotherapy meeting
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
Published: 2021-03-30 (Crawled : 17:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: 0.32%
H: 1.55%
C: -0.61%
presentation disease
Urticaria Drugs Market size to grow by USD 1.31 billion from 2021 to 2026, Driven by the growth in incidence of urticaria - Technavio
Published: 2023-04-04 (Crawled : 22:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.79%
H: 3.07%
C: 3.07%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.57%
H: 1.01%
C: 0.96%
VTRS | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.1%
H: 3.15%
C: 2.94%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.29%
H: 0.83%
C: 0.4%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.2%
H: 1.32%
C: 1.24%
SNY | News | $46.385 2.19% 3M
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: 0.0%
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -0.96%
H: 1.21%
C: -0.24%
urticaria growth market
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
ASNS | $0.828 21.75% 17.86% 18K
|
UONE | $2.36 19.8% 16.53% 75K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.